Novo Nordisk is ramping up its use of artificial intelligence to dramatically reduce the time needed to launch new drugs, as the Danish pharmaceutical giant looks to strengthen its position in the fast-growing obesity treatment market. Speaking at a Reuters summit in Bengaluru, senior executive John Dawber said AI is helping cut months from the […]Continue Reading
